SEC Tracker
Get the app

Halozyme Therapeutics HALO

Halozyme Therapeutics Q1 FY25: revenue $264.9M, up 35%; diluted EPS $0.93

Form
10-Q
Filed
Period
Importance
Notable
Document
10-Q
Exhibit 10.1
Material contract
Exhibit 10.2
Material contract

Key figures from this report

These are the numbers Halozyme Therapeutics reported for Q1 FY25, the quarter ended Mar 31, 2025, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Revenue$264.9M+35% from $195.9M in Q1 FY2410-Q income statement, on EDGAR
  2. Net income$118.1M+54% from $76.8M in Q1 FY2410-Q income statement, on EDGAR
  3. Diluted EPS$0.93+55% from $0.60 in Q1 FY2410-Q income statement, on EDGAR
  4. Cash and cash equivalents$176.3M+7% from $164.6M in Q1 FY2410-Q balance sheet, on EDGAR
  5. Cash from operations$154.2M+19% from $129.4M in Q1 FY2410-Q cash flow statement, on EDGAR

Every quarter in the financial tables

View on EDGAR

Open in the app

Get an email when Halozyme Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2836 and related industry codes: the same peer list as the financial tables.

  1. Axsome Therapeutics AXSM public float $4.4B, Jun 30, 2025
  2. Alkermes ALKS public float $4.7B, Jun 30, 2025
  3. Lantheus Holdings LNTH public float $4.3B, Jun 30, 2025
  4. Adma Biologics ADMA public float $4.2B, Jun 30, 2025
  5. Soleno Therapeutics SLNO public float $4.1B, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.